Nasdaq

Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC

Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...
Seeking Alpha

Outcomes From Two New Head-to-Head Randomized Controlled Trials Involving the UroLift™ System Highlight a Superior Patient Experience* Against Rezūm and Its Advantage Over ...

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American ...
Nasdaq

Teleflex Incorporated Reports Positive Clinical Data for UroLift™ System at AUA 2025, Highlighting Improved Patient Satisfaction and Outcomes for BPH Treatment

Teleflex Incorporated presented new clinical data at the 2025 American Urological Association Annual Meeting, highlighting the UroLift™ System as a leading minimally invasive treatment for benign ...
Hosted on MSN

Teleflex Highlights UroLift™ System’s Clinical Advantages at 2025 AUA Meeting

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) presented significant clinical findings at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas. The data from two randomized ...
KRQE Blogs

Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types

WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced ...
Seeking Alpha

Teleflex Launches National Ad Campaign — “Pit Stop” — to Raise Awareness of the UroLift® System as a Treatment for Enlarged Prostate

WAYNE, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX) (NYSE: TFX), a leading global provider of medical technologies, today announced the launch of a new national advertising ...